KATIE CLEMENTS: Open Payments
NPI 1952954331 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,685 in 53 payments from 19 companies in 2025. Trend: 2023 $774 · 2024 $1,109 · 2025 $1,685
Food & beverage: $1,586Education: $99
| Company | Payments | Amount |
|---|---|---|
| MERZ NORTH AMERICA, INC. | 8 | $543 |
| Novo Nordisk Inc | 9 | $221 |
| Astellas Pharma US Inc | 4 | $177 |
| Lilly USA, LLC | 8 | $146 |
| Madrigal Pharmaceuticals | 1 | $108 |
| ABBVIE INC. | 4 | $107 |
| AstraZeneca Pharmaceuticals LP | 3 | $70 |
| Exact Sciences Corporation | 3 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| Globus Medical, Inc. | 2 | $31 |
Products named: Xeomin, MOUNJARO, Wegovy, REZDIFFRA, Rybelsus, Veozah, AIRSUPRA, CREON.
Industry payments across MD — which companies pay providers there.
